June 4-8, 2021; Online at https://conferences.asco.org/am
Results of this preplanned interim analysis demonstrated significantly improved DFS with adjuvant atezolizumab in patients with stage II-IIIA NSCLC, particularly for individuals with PD-L1–positive tumors.